Exelixis to Webcast Investor Conference Chats in May 2024
Exelixis, Inc. (Nasdaq: EXEL), headquartered in Alameda, California, has revealed that its management team will be participating in a series of fireside chats at upcoming investor conferences in May. These engagements are part of the company's efforts to engage with the investment community and provide updates on its ongoing projects and future aspirations in the healthcare sector.
The first conference is the BofA Securities 2024 Health Care Conference, where Exelixis will present at 2:20 p.m. Eastern Time (ET) or 11:20 a.m. Pacific Time (PT) on Tuesday, May 14 in Las Vegas. This presentation will offer insights into the company's recent advancements and strategic initiatives in oncology.
On the same day, Exelixis is set to present at the Citizens JMP Life Sciences Conference at 9:30 a.m. ET or 6:30 a.m. PT in New York City. This event will provide another platform for the company to discuss its innovative pipeline and the potential impact of its novel therapies on cancer treatment.
Additionally, Exelixis will participate in the RBC Capital Markets 2024 Global Healthcare Conference at 2:35 p.m. ET or 11:35 a.m. PT on May 14, also in New York City. This session will further elaborate on the company's mission and its ongoing commitment to developing transformational treatments for cancer patients.
These presentations will be accessible via webcast, and interested parties can log onto the Event Calendar page under the Investors & News section on the Exelixis website. The company will also provide replays of the webcasts, available for at least 30 days after the events.
Exelixis is recognized globally for its ambition in the oncology field, focusing on creating next-generation medicines and regimens that push the boundaries of cancer care. The company’s approach leverages its expertise in drug discovery and development, aiming to build a diverse portfolio of products targeting various tumor types and indications. This includes a pipeline of small molecules, antibody-drug conjugates, and other biotherapeutics.
The cornerstone of Exelixis’ commercial portfolio is CABOMETYX® (cabozantinib), a flagship product that has significantly impacted cancer treatment. The company’s strategy involves a robust investment in scientific research and partnerships, which drives the advancement of its investigational programs and expands the therapeutic reach of its existing products.
Exelixis’ commitment is fueled by a bold scientific vision to develop transformative treatments that offer hope and improved outcomes for cancer patients.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
